Cepharanthine suppresses osteoclast formation by modulating the nuclear factor ‐κB and nuclear factor of activated T‐cell signaling pathways

In this study, we found that CEP inhibited receptor activator of nuclear factor‐κB (NF‐κB) ligand (RANKL)‐induced osteoclast formation and bone‐resorbing activities using osteoclastogenesis and bone resorption assay. By polymerase chain reaction, we also found that CEP inhibited the expression of osteoclast‐differentiation marker genes includingCtsk,Calcr,Atp6v0d2,Mmp9 andNfatc1. Mechanistic analyses including Western blot and luciferase reporter assay revealed that CEP inhibited RANKL ‐induced activation of NF‐κB and nuclear factor of activated T‐cell, which are essential for the formation of osteoclast. Collectively, these data suggested that CEP can potentially be used as an alternative therapy for preventing or treating osteolytic diseases.

Source: Journal of Cellular Biochemistry - November 13, 2018 Category: Biochemistry Authors: Xixi Lin, Fangming Song, Lin Zhou, Ziyi Wang, Chengming Wei, Jiake Xu, Jinmin Zhao, Qian Liu Tags: RESEARCH ARTICLE Source Type: research